Patent Supporting Diabetic Nephropathy – XRx-221
XORTX Therapeutics Inc.
Calgary, Alberta, CANADA
CALGARY, Alberta, April 06, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing therapeutics for the treatment of progressive kidney disease, is pleased to announce that it has received notification of intention to grant the patent “Compositions and Methods for Treatment and Prevention of Hyperuricemia Related Health Consequences” by the European Patent Office for this PCT international application.
› Read more